We are currently executing a mandate to identify established industrial and medical device companies suitable for access to U.S. public capital, Nasdaq.
The focus is on founder- or fund-owned businesses with audited accounts, multi-hundred-million revenues, and durable operating profit, where boards are evaluating succession, portfolio exit, or capital expansion beyond a conventional trade sale.
The mandate is directed at European companies operating in defence and dual-use manufacturing, power and electrical equipment, energy hardware, and cleared medical devices with existing commercial traction. However, other geographic area companies may qualify.
The relevant situations are usually one of four:
- A founder considering succession.
- A fund seeking a credible exit path.
- A group evaluating the separation of a division.
- A company that is too substantial for a private sale but still too small for a conventional local listing.
The issue is not simply whether a business is good. The issue is whether it can access the right institutional capital, in the right market, with a structure suited to its scale, governance, and sector.
For the right company, a U.S. listing pathway can offer an alternative to a trade sale, a delayed process, or a financing route that never quite opens locally.
CFOs, CEOs, founders, and investment committee members who wish to explore whether a company fits this profile are welcome to contact us directly for an initial exchange.